Second Dicerna Hepatic Disease Target Option Exercise
Boehringer Ingelheim Exercises Option on Second Hepatic Disease Target From Research Collaboration with Dicerna Collaboration seeks to develop novel treatments for chronic liver diseases, including nonalcoholic steatohepatitis (NASH)
Source: Boehringer Ingelheim Corporate News - Category: Research Source Type: news